|
Common name |
B-hAMHR2 ID8 | Catalog number | 311531 |
| Aliases | AMHR, MISR2, MISRII, MRII | Disease | Ovarian cancer |
|
Organism |
Mouse |
Strain | C57BL/6 |
| Tissue types | Ovary | Tissue | Ovary |
Description
B-hAMHR2 ID8 cells have the capability to establish tumors in vivo and can be used for efficacy studies.
Subcutaneous homograft tumor growth of B-hAMHR2 MC38 cells. B-hAMHR2 MC38 cells (5x105) and wild-type ID8 cells (5x105) were subcutaneously implanted into C57BL/6N mice (female, 7-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hAMHR2 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.
Protein expression analysis of tumor cells
B-hAMHR2 ID8 cells were subcutaneously transplanted into C57BL/6 mice (n=5), and on 23 days post inoculation, tumor cells were harvested and assessed for human AMHR2 expression by flow cytometry. As shown, human AMHR2 was highly expressed on the surface of tumor cells. Therefore, B-hAMHR2 ID8 cells can be used for in vivo efficacy studies of novel AMHR2 therapeutics.
